STADA Pharmaceuticals Australia
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From STADA Pharmaceuticals Australia
US-based giant Amgen has seen its Mvasi biosimilar become the sole bevacizumab product listed on Australia’s Pharmaceutical Benefits Scheme.
Danish firm picks up portfolio and manufacturing sites, along with around 600 employees.
Stada is looking to add value to Australia’s anesthetics market by introducing BioQ Pharma’s ready-to-use Propofusor propofol device.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in August 2017.